Cargando…
Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
PURPOSE: Lower-grade glioma (LGG) is rare among patients above the age of 60 (“elderly”). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to questio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992027/ https://www.ncbi.nlm.nih.gov/pubmed/36648586 http://dx.doi.org/10.1007/s11060-022-04230-1 |
_version_ | 1784902258700320768 |
---|---|
author | Dao Trong, P. Gluszak, M. Reuss, D. von Deimling, A. Wick, A. König, L. Debus, J. Herold-Mende, C. Unterberg, A. Jungk, C. |
author_facet | Dao Trong, P. Gluszak, M. Reuss, D. von Deimling, A. Wick, A. König, L. Debus, J. Herold-Mende, C. Unterberg, A. Jungk, C. |
author_sort | Dao Trong, P. |
collection | PubMed |
description | PURPOSE: Lower-grade glioma (LGG) is rare among patients above the age of 60 (“elderly”). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to question this paradigm analyzing a contemporary cohort of patients with IDH mutant astrocytoma and oligodendroglioma WHO grade 2 and 3. METHODS: Elderly patients treated in our department for a supratentorial, hemispheric LGG between 2009 and 2019 were retrospectively analyzed for patient-, tumor- and treatment-related factors and progression-free survival (PFS) and compared to patients aged under 60. Inclusion required the availability of subtype-defining molecular data and pre- and post-operative tumor volumes. RESULTS: 207 patients were included, among those 21 elderlies (10%). PFS was comparable between elderly and younger patients (46 vs. 54 months; p = 0.634). Oligodendroglioma was more common in the elderly (76% vs. 46%; p = 0.011). Most patients underwent tumor resection (elderly: 81% vs. younger: 91%; p = 0.246) yielding comparable residual tumor volumes (elderly: 7.8 cm(3); younger: 4.1 cm(3); p = 0.137). Adjuvant treatment was administered in 76% of elderly and 61% of younger patients (p = 0.163). Uni- and multi-variate survival analyses identified a tumor crossing the midline, surgical strategy, and pre- and post-operative tumor volumes as prognostic factors. CONCLUSION: Elderly patients constitute a small fraction of molecularly characterized LGGs. In contrast to previous reports, favorable surgical and survival outcomes were achieved in our series comparable to those of younger patients. Thus, intensified treatment including maximal safe resection should be advocated in elderly patients whenever feasible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-022-04230-1. |
format | Online Article Text |
id | pubmed-9992027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-99920272023-03-09 Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort Dao Trong, P. Gluszak, M. Reuss, D. von Deimling, A. Wick, A. König, L. Debus, J. Herold-Mende, C. Unterberg, A. Jungk, C. J Neurooncol Case Study PURPOSE: Lower-grade glioma (LGG) is rare among patients above the age of 60 (“elderly”). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to question this paradigm analyzing a contemporary cohort of patients with IDH mutant astrocytoma and oligodendroglioma WHO grade 2 and 3. METHODS: Elderly patients treated in our department for a supratentorial, hemispheric LGG between 2009 and 2019 were retrospectively analyzed for patient-, tumor- and treatment-related factors and progression-free survival (PFS) and compared to patients aged under 60. Inclusion required the availability of subtype-defining molecular data and pre- and post-operative tumor volumes. RESULTS: 207 patients were included, among those 21 elderlies (10%). PFS was comparable between elderly and younger patients (46 vs. 54 months; p = 0.634). Oligodendroglioma was more common in the elderly (76% vs. 46%; p = 0.011). Most patients underwent tumor resection (elderly: 81% vs. younger: 91%; p = 0.246) yielding comparable residual tumor volumes (elderly: 7.8 cm(3); younger: 4.1 cm(3); p = 0.137). Adjuvant treatment was administered in 76% of elderly and 61% of younger patients (p = 0.163). Uni- and multi-variate survival analyses identified a tumor crossing the midline, surgical strategy, and pre- and post-operative tumor volumes as prognostic factors. CONCLUSION: Elderly patients constitute a small fraction of molecularly characterized LGGs. In contrast to previous reports, favorable surgical and survival outcomes were achieved in our series comparable to those of younger patients. Thus, intensified treatment including maximal safe resection should be advocated in elderly patients whenever feasible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-022-04230-1. Springer US 2023-01-17 2023 /pmc/articles/PMC9992027/ /pubmed/36648586 http://dx.doi.org/10.1007/s11060-022-04230-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Case Study Dao Trong, P. Gluszak, M. Reuss, D. von Deimling, A. Wick, A. König, L. Debus, J. Herold-Mende, C. Unterberg, A. Jungk, C. Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort |
title | Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort |
title_full | Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort |
title_fullStr | Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort |
title_full_unstemmed | Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort |
title_short | Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort |
title_sort | isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort |
topic | Case Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992027/ https://www.ncbi.nlm.nih.gov/pubmed/36648586 http://dx.doi.org/10.1007/s11060-022-04230-1 |
work_keys_str_mv | AT daotrongp isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT gluszakm isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT reussd isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT vondeimlinga isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT wicka isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT konigl isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT debusj isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT heroldmendec isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT unterberga isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort AT jungkc isocitratedehydrogenasemutantlowergradegliomainelderlypatientstreatmentandoutcomeinamolecularlycharacterizedcontemporarycohort |